184 related articles for article (PubMed ID: 26856927)
1. Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.
Bancroft T; Lim J; Wang C; Sander SD; Swindle JP
Clin Ther; 2016 Mar; 38(3):545-56.e1-6. PubMed ID: 26856927
[TBL] [Abstract][Full Text] [Related]
2. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
Reynolds SL; Ghate SR; Sheer R; Gandhi PK; Moretz C; Wang C; Sander S; Costantino ME; Annavarapu S; Andrews G
Health Qual Life Outcomes; 2017 Jun; 15(1):128. PubMed ID: 28637460
[TBL] [Abstract][Full Text] [Related]
3. Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin.
Song X; Gandhi P; Gilligan AM; Arora P; Wang C; Henriques C; Sander S; Smith DM
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):213-222. PubMed ID: 28649894
[TBL] [Abstract][Full Text] [Related]
4. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation.
Francis K; Yu C; Alvrtsyan H; Sander S; Ghosh S; Rao Y; Sanchez H; Matchar D
Curr Med Res Opin; 2015 Dec; 31(12):2189-95. PubMed ID: 26359333
[TBL] [Abstract][Full Text] [Related]
5. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
[TBL] [Abstract][Full Text] [Related]
6. All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.
Gilligan AM; Gandhi P; Song X; Wang C; Henriques C; Sander S; Smith DM
Am J Cardiovasc Drugs; 2017 Dec; 17(6):481-492. PubMed ID: 28795348
[TBL] [Abstract][Full Text] [Related]
7. Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin.
Fonseca E; Sander SD; Hess GP; Ghosh S
J Manag Care Spec Pharm; 2015 Nov; 21(11):1039-53. PubMed ID: 26521116
[TBL] [Abstract][Full Text] [Related]
8. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
9. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
10. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
[TBL] [Abstract][Full Text] [Related]
11. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
12. Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United States.
Deitelzweig SB; Evans M; Trocio J; Gupta K; Lingohr-Smith M; Menges B; Lin J
Clin Appl Thromb Hemost; 2018 Mar; 24(2):364-371. PubMed ID: 28135822
[TBL] [Abstract][Full Text] [Related]
13. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation.
Deitelzweig S; Evans M; Hillson E; Trocio J; Bruno A; Tan W; Lingohr-Smith M; Singh P; Lin J
Curr Med Res Opin; 2016; 32(1):87-94. PubMed ID: 26451675
[TBL] [Abstract][Full Text] [Related]
14. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
[TBL] [Abstract][Full Text] [Related]
16. Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.
Coleman CI; Tangirala M; Evers T
PLoS One; 2016; 11(6):e0157769. PubMed ID: 27327275
[TBL] [Abstract][Full Text] [Related]
17. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
Curr Med Res Opin; 2014 Aug; 30(8):1521-8. PubMed ID: 24758611
[TBL] [Abstract][Full Text] [Related]
18. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation.
Nelson WW; Song X; Thomson E; Smith DM; Coleman CI; Damaraju CV; Schein JR
Curr Med Res Opin; 2015; 31(10):1831-40. PubMed ID: 26211816
[TBL] [Abstract][Full Text] [Related]
19. Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation.
Nelson WW; Wang L; Baser O; Damaraju CV; Schein JR
J Med Econ; 2015 May; 18(5):333-40. PubMed ID: 25549062
[TBL] [Abstract][Full Text] [Related]
20. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation.
Ghate SR; Biskupiak J; Ye X; Kwong WJ; Brixner DI
J Manag Care Pharm; 2011 Nov; 17(9):672-84. PubMed ID: 22050392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
